|Systematic (IUPAC) name|
|Mol. mass||220.268 g/mol|
1-(3,4-Methylenedioxybenzyl)piperazine (MDBZP, piperonylpiperazine) is a psychoactive drug of the piperazine chemical class related to benzylpiperazine (BZP). In the book PiHKAL it is speculated that MDBZP might have effects similar to the drug 3,4-methylenedioxy-N-methylamphetamine (MDMA; “Ecstasy”) because of the presence of the 3,4-methylenedioxy group on the benzene ring; however, once the compound was tested in humans this theory was shown to be incorrect.
MDBZP has been sold as a “designer drug” with supposed recreational properties, and has even been found as an ingredient in street “Ecstasy” pills. However, MDBZP is only a very mild stimulant, and does not produce euphoria, empathogenic or psychedelic effects. The prominent side effects produced by MDBZP are dizziness, nausea and headaches, but at high doses it has been known to cause convulsions. MDBZP thus has all of the negative side effects of other piperazine derivatives, but without any of the positive effects that might make these drugs desirable to consumers.
Little is currently known about MDBZP due to its virtually nonexistent contributions to any medicinal, commercial, educational, or recreational use.
- Piribedil — antiparkinsonian agent
- 3,4-methylenedioxy-N-methylamphetamine (MDMA)
- 1-Benzylpiperazine (BZP)
- 1-Methyl-4-benzylpiperazine (MBZP)
- 1,4-Dibenzylpiperazine (DBZP)
- 3-Chlorophenylpiperazine (mCPP)
- 3-Trifluoromethylphenylpiperazine (TFMPP)
- 4-Bromo-2,5-dimethoxy-1-benzylpiperazine (2C-B-BZP)
- 4-Fluorophenylpiperazine (pFPP)
- 4-Methoxyphenylpiperazine (MeOPP)